Compound anti-cancer drug

Abstract

The invention relates to a compound anti-cancer drug. The drug consists of diethyl dithiocarbamate (DTC) and 12-oxo-tetradecanoyl phorbol-13-acetate (TPA). The novel anti-cancer drug, through combinedapplication of the phorbol compound (TPA) and the dithiocarbamate compound (DTC), can achieve an effect of conducting optimal treatment on cancers, with efficacy better than that of individual drugs,and a good inhibitory effect can be achieved on myeloid leukemia; in addition, the compound drug, in cancer treatment, is low in administration dosage and lower in administration concentration than individual drugs, so that toxic and side effects of the drug are reduced and harm to human body is relieved; and the compound anti-cancer drug is relatively low cheap, so that economic burden of patients is reduced.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a composite anticancer drug. Background technique [0002] Cancer is a serious threat to people's lives and health. The latest edition of the "World Cancer Report" released by the World Health Organization (WHO) in 2014 predicts that cancer cases will show a rapid increase, from 14 million in 2012 to 19 million in 2025. million, and will reach 24 million by 2035. With the increase of people's life and work pressure and the change of diet structure, the probability of people suffering from cancer has increased significantly. The latest cancer status released by the National Cancer Center in 2017 shows that about 10,000 people are diagnosed with cancer every day in the country, and the incidence rate ranks 74th in the world. , the number of morbidity ranks first in the world; the death rate ranks 29th in the world. Cancer has seriously threatened the quality of life and life ...

AI Technical Summary

Problems solved by technology

However, this treatment method is not ideal for non-APL AML patients, and the main treatment drugs are Cytarabine (Cytarabine) drugs

Even though breakthroughs have been made in the clinical treatment of acute myeloid leukemia, due to individual differences in efficacy, drug resistance, relapse rate and other refractory conditions, the development of low-toxic and effective drugs has become the key to controlling and reducing leukemia mortality. a major challenge

Images